ArticleMolecular genetics & genomic medicine2026
A Novel De Novo MTM1 Insertion Frameshift Variant Causes X-Linked Myotubular Myopathy in a Chinese Female.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMTM1-related X-linked myotubular myopathy (XLMTM) typically affects males; however, symptomatic female carriers may occur.
methodsWe evaluated a 24-year-old woman with infantile hypotonia followed by slowly progressive, asymmetric proximal weakness with facial and ocular involvement. Clinical assessment, pulmonary function testing, electromyography, lower-limb muscle MRI, and muscle biopsy were performed. Next-generation sequencing and parental segregation analysis were conducted.
resultsThe patient developed progressive functional decline leading to wheelchair dependence. Investigations showed moderate-to-severe restrictive ventilatory impairment, a myopathic pattern on electromyography, and extensive fatty replacement on muscle MRI. Muscle biopsy demonstrated histopathological features consistent with centronuclear myopathy. Genetic testing identified a heterozygous MTM1 insertion, c.1266_1267insATGGTGATAAAAACCATTCA, predicted to cause a frameshift (p.Gly423MetfsTer48). The variant was absent in both parents, supporting a de novo event. To our knowledge, this MTM1 variant has not been previously reported.
conclusionThis case expands the MTM1 variant spectrum and highlights that de novo MTM1 frameshift variants can underlie clinically significant XLMTM manifestations in females, underscoring the value of genetic testing in symptomatic women with centronuclear myopathy features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.